Posted by Michael Wonder on 31 Jul 2020
Medicare expands coverage for BRACAnalysis CDx in prostate cancer
31 July 2020 - Myriad Genetics announced today that Medicare has expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza (olaparib).
BRACAnalysis CDx is the only germline test covered for this indication.
In May, the U.S. FDA approved the BRACAnalysis CDx test for use as a companion diagnostic tool by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza (olaparib).
